Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates

By Karen Roman

Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden.

The global TENACITY-01 study had an 85.7% overall response rate, with a complete remission rate of 71.4% in adults with the types of cancers described above, the company stated.

Never Miss our Weekly Highlights HERE

The second presentation showed an 80% complete remission rate in pediatric patients with the leukemia and lymphoma cancers previously mentioned in a phase 1/2 study using CTD402 allogeneic CAR T-cell therapy, it said.

“The combination of strong efficacy—with 80% of pediatric patients achieving complete remission—and a favorable safety profile, alongside CTD402’s immediate availability as an off-the-shelf therapy, demonstrates the potential to address a critical unmet need in this patient population,” said Jan Davidson-Moncada, MD, PhD., Imviva Biotech Chief Medical Officer.